ZDHHC16

Across TCGA pan-cancer cohorts, ZDHHC16 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZDHHC16 data layer compared with 29 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ZDHHC16 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZDHHC16 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

COAD, PRAD, and UCEC are the cancer types where ZDHHC16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	II,III,IV	0.166	0.652	.010	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →
BLCA	DFS	Median	II,III,IV	1.000	0.325	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZDHHC16–COAD (OS)

Open the COAD breakdown →